Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Distinct Patterns of Somatic Genomic Alterations and Mutational Signatures in Central and Peripheral-Type Small-Cell Lung Cancer
33 Pages Posted: 20 May 2020
More...Abstract
Background: Only a few studies have mentioned the differences in survival between patients with central and peripheral-type small-cell lung cancer (SCLC). Genomic landscape and genetic heterogeneity between central and peripheral-type SCLC is scarce.
Methods: A total of 41 tumor/control pairs were to move forward for whole-exome sequencing. Distinct patterns of somatic genomic alterations and mutational signatures in central and peripheral-type SCLCs were analyzed.
Findings: Tumor mutation burden (TMB) of peripheral-type SCLCs were higher than central-type. And smoking patients had significantly higher weighted genome instability index (wGII) and copy number alteration (CNA) burden than the non-smokers in SCLCs, these alterations were more obviosly in central-types. Furthermore, the driver recurrent somatic CNA (SCNA) regions of central and peripheral-type SCLCs were different. Central and peripheral-type SCLCs had no common recurrent amplification cytobands or genes, but had common recurrent deletion inculding 4 cytobands and 5 genes. Interestingly, the recurrent amplification 12q24.31 was negative correlation with overall survival (OS) in central but not peripheral-type. Moreover, a de novo signature A was found significantly higher in peripheral than central-type SCLCs. In parallel, signature D was predictive of poor outcome, which was mainly in peripheral SCLC patients. COSMIC signatures analysis revealed that the association with signature D and OS was similar to the positive relationship between signature 13 and outcome.
Interpretation: Although central and peripheral-type SCLCs had similar significantly mutated genes (SMGs), immunotherapy response, genome instability, the driver SCNAs and mutational signatures may be largely distinct. These mutations leaded to different prognosis between central and peripheral-type SCLCs.
Funding Statement: None
Declaration of Interests: The authors declare no competing interests.
Ethics Approval Statement: Experimental plans and protocols for this study (NO K18-203Y) were approved by the ethics/licensing committee of the Shanghai Pulmonary Hospital for review and confirmation. Written informed consent was obtained from all patients participating in the study.
Keywords: Small cell lung cancers (SCLCs); Whole-exome sequencing (WES); Bioinformatics; Tumor mutation burden (TMB); Somatic copy number alterations (SCNAs); De novo signature
Suggested Citation: Suggested Citation